Showing results (451-460 of 532) with videos related to

Sort By:
Pageof 54
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 1, 2026
Performance evaluation of an automated mass spectrometry system for the measurement and isotyping of monoclonal immunoglobulinsJamie Ashby, Daniel McEntee, Dhananjay Sakrikar, et al.
Cell Reports|July 21, 2015
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional ActivationAldo M Roccaro, Yuji Mishima, Antonio Sacco, et al.
Blood|September 1, 2007
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaXavier Leleu, Xiaoying Jia, Judith Runnels, et al.
British Journal of Haematology|April 26, 2014
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomideAndrew J Yee, Parameswaran Hari, Raffaella Marcheselli, et al.
Cancer Research|April 19, 2007
Proteomic analysis of waldenstrom macroglobulinemiaEvdoxia Hatjiharissi, Hai Ngo, Alexey A Leontovich, et al.
Blood|November 5, 2020
Progression signature underlies clonal evolution and dissemination of multiple myelomaYu Jia Shen, Yuji Mishima, Jiantao Shi, et al.
Blood|September 14, 2014
Pyk2 promotes tumor progression in multiple myelomaYu Zhang, Michele Moschetta, Daisy Huynh, et al.
Blood|November 5, 2008
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemiaXavier Leleu, Lian Xu, Xiaoying Jia, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2014
Engineered nanomedicine for myeloma and bone microenvironment targetingArchana Swami, Michaela R Reagan, Pamela Basto, et al.
The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.
Pageof 54